NO. 4 THE FORUM, ST. HELIER, Y9
Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Director Retirement - Timothy Scannell Steps Down from Board
News
Reports Second Quarter 2026 Financial Results
Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
Election of Directors at NovoCure Limited Annual Meeting
Reports First Quarter 2026 Financial Results
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
S-8 POS